ONTX - Onconova Therapeutics (ONTX) - All Trials Continue Toward Data Milestones

2Q22 Onconova Reported Trial Progress. 2Q22 loss of $4.0 million or $(0.19) per share, compared with our estimated loss of $3.7 million or $(0.18) per share. Several clinical trials for both narazaciclib and rigosertib are continuing as expected. The company ended the quarter with $46.5 million in cash and cash equivalents.Both Narazaciclib Phase 1/2 Trials Continue To Enroll Patients. The two trials testing narazaciclib at different treatment schedules continue to treat patients. The trial in China continues in its fifth cohort while the US trial recently begun dosing its fifth cohort. Neither trial has reached its maximum tolerated dose and none of the toxicities associated with other CDK4/6 drugs have been reported. We expect announcement of the dosing level selected for Phase 2 around 4Q22. Read More >>